Q32 Bio and Horizon are collaborating to develop bempikibart, a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, two key immune pathways.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2022 | $74.00 | Neutral | H.C. Wainwright |
| 8/4/2022 | Outperform → Mkt Perform | SVB Leerink | |
| 6/14/2022 | $139.00 | Buy | UBS |
| 6/6/2022 | $95.00 | Mkt Perform | SVB Leerink |
| 5/23/2022 | $95.00 | Mkt Perform | SVB Leerink |
| 3/15/2022 | $140.00 | Outperform | Oppenheimer |
| 3/2/2022 | $135.00 → $140.00 | Overweight | Morgan Stanley |
| 12/8/2021 | $137.00 | Overweight | Wells Fargo |
H.C. Wainwright initiated coverage of Horizon Pharma with a rating of Neutral and set a new price target of $74.00
SVB Leerink downgraded Horizon Pharma from Outperform to Mkt Perform
UBS initiated coverage of Horizon Pharma with a rating of Buy and set a new price target of $139.00
Horizon Therapeutics's (NYSE:HZNP) short percent of float has fallen 25.18% since its last report. The company recently reported that it has 7.10 million shares sold short, which is 3.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.38 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short
-8-K As previously disclosed, on December 11, 2022, Horizon Therapeutics plc (“Horizon”), Amgen Inc. (“Amgen”) and Pillartree Limited, a whollyowned subsidiary of Amgen (“Acquirer Sub”), entered into a Transaction Agreement pursuant to which, among other things, Acquirer Sub willacquire the entire issued ordinary share capital of Horizon (the “Acquisition”) through a court-sanctioned scheme of arrangement underChapter 1 of Part 9 of the Irish Companies Act 2014 (the “Scheme”).On October 5, 2023, the High Court of Ireland (the “Court”) sanctioned the Scheme. Completion of the Acquisition remains subject to thedelivery to the Registrar of Companies in Ireland of a copy of the order of the Cou
Horizon Therapeutics (NASDAQ:HZNP) has outperformed the market over the past 5 years by 36.06% on an annualized basis producing an average annual return of 44.12%. Currently, Horizon Therapeutics has a market capitalization of $26.62 billion. Buying $100 In HZNP: If an investor had bought $100 of HZNP stock 5 years ago, it would be worth $640.52 today based on a price of $116.23 for HZNP at the time of writing. Horizon Therapeutics's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga'
SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)
SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)
SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
LOS ANGELES, Jan. 11, 2022 /PRNewswire/ -- ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria, BSN, as the company's chief operating officer (COO). In this role, Ms. Gloria will oversee business operations across the company. A former oncology nurse, Ms. Gloria has two decades' experience in the biotechnology industry having led a variety of research and development (R&D
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to the Scheme becoming effective Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces that
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION October 5, 2023 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to the outcome of the Court Sanction Hearing Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces that the Irish H
Horizon Therapeutics plc (NASDAQ:HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION (a) Full name of discloser: Gino Santini (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securit
15-12G - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement of Date of Court Hearing Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces today that, in relation to the offer for the Company by Pillartre
THOUSAND OAKS, Calif. and DUBLIN, Sept. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon. As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the U.S. District Court for the Northern District of Illinois, and that Amgen and Horizon will quickly see
Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831157622/en/ As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the U.S. District Court for the Northern D